Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299050 | 0.77 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL3833786 | 0.73 | — | — | |
| SCHEMBL20863059 | 0.71 | CYP2D6 (0.54) | CYP2D6 | |
| SCHEMBL20610173 | 0.71 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL23425128 | 0.69 | CYP2D6 (0.32) | CYP2D6ALDH1A1 | |
| SCHEMBL643574 | 0.67 | CYP2D6 (0.41) | CYP2D6ALDH1A1 | |
| SCHEMBL20610036 | 0.67 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL20618378 | 0.67 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL21013278 | 0.66 | — | — | |
| SCHEMBL3835379 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066980-A1 | 4-AMINOPHENYLPHOSPHORYLCHOLINE COMPOUNDS FOR BLOCKING C-REACTIVE PROTEIN | PENTRACOR GMBH (DE) | 2023-04-27 | — | — | WO | disclosed |
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-09-26 | — | — | US | disclosed |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | PURDUE PHARMA L.P. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | CYP2D6 190/4885ALDH1A1 559/4885 |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | CYP2D6 190/4885ALDH1A1 559/4885 |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | TRPC5, TRPV5, TRPV1 | CYP2D6 190/4885ALDH1A1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.